Similarly, HGF/c-Met inhibitors such as tivantinib failed to improve survival in advanced hepatocellular carcinoma (METIV-HCC, NCT01755767), raising caution for analogous strategies in CCA (72). Here, MET is linked to hepatocellular carcinoma.